Stockscreener 앱 받기
2.50
17.37%
0.37
시간 외 거래:
2.50
전일 마감가:
$2.13
열려 있는:
$2.5
하루 거래량:
24.26M
Relative Volume:
7.22
시가총액:
$139.78M
수익:
$76.19M
순이익/손실:
$-1.61M
주가수익비율:
250.00
EPS:
0.01
순현금흐름:
$28.98M
1주 성능:
+259.04%
1개월 성능:
+272.58%
6개월 성능:
+119.30%
1년 성능:
+76.06%
1일 변동 폭
$2.35
$2.80
1주일 범위
$0.6562
$2.80
52주 변동 폭
$0.5052
$2.80
Spero Therapeutics Inc Stock (SPRO) Company Profile
명칭
Spero Therapeutics Inc
전화
857-242-1600
주소
675 MASSACHUSETTS AVENUE, CAMBRIDGE, MA
SPRO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SPRO
Spero Therapeutics Inc
|
2.50 | 38.93M | 76.19M | -1.61M | 28.98M | 0.01 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Spero Therapeutics Inc Stock (SPRO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-20 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-09-23 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2021-10-01 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2021-01-22 | 재확인 | H.C. Wainwright | Buy |
| 2020-12-16 | 개시 | Berenberg | Buy |
| 2020-09-29 | 개시 | Evercore ISI | Outperform |
| 2019-11-05 | 재확인 | H.C. Wainwright | Buy |
| 2019-09-09 | 개시 | Janney | Buy |
| 2018-02-09 | 개시 | Cantor Fitzgerald | Overweight |
| 2017-11-27 | 개시 | BofA/Merrill | Neutral |
| 2017-11-27 | 개시 | Oppenheimer | Outperform |
| 2017-11-27 | 개시 | Stifel | Buy |
모두보기
Spero Therapeutics Inc 주식(SPRO)의 최신 뉴스
Why Spero Therapeutics, Inc. (SPRO) Surged Last Week - Insider Monkey
Spero Therapeutics stock hits 52-week high at $2.53 By Investing.com - Investing.com Canada
Spero Therapeutics stock hits 52-week high at $2.53 - Investing.com India
Spero Therapeutics Jumps as Oral Carbapenem Hits Phase 3 Milestone - MSN
SPRO Stock Soars 245% on GSK-Partnered UTI Drug Meeting Study Goal - MSN
Spero Therapeutics Stock (SPRO) Rockets 225% on Clinical Trial Data - The Globe and Mail
Spero Therapeutics And 2 Other Promising Penny Stocks To Watch - Yahoo Finance
Spero Therapeutics rockets on positive Phase III study for tebipenem HBr - The Pharma Letter
Biotech Finds Mid-Week Success After Meeting Primary Endpoint - The Globe and Mail
GSK’s Bet On Spero’s Oral cUTI Antibiotic Poised To Pay Off With New Phase III Data - insights.citeline.com
Spero Therapeutics Stock Skyrockets on Strong Phase 3 Trial Results - MSN
Spero Therapeutics (SPRO) Stock Explodes: Shares Skyrocket Over 200% in Stunning Midday Rally! - Daily Chhattisgarh News
Why Is GSK Partner Spero Therapeutics Stock Skyrocketing On Wednesday? - Benzinga
GSK, Spero stop UTI drug trial after early success - Reuters
GSK, Spero Therapeutics Stop Antibiotic Trial For Complicated Urinary Tract Infections Early After Positive Results, Retail’s Thrilled By Stocktwits - Investing.com India
Spero Therapeutics (SPRO) Soars 255% on Phase 3 Success - GuruFocus
Pre-market Movers: SPRO, ASBP, IFRX, IMNN... - RTTNews
Spero Therapeutics stock soars on positive phase 3 trial results By Investing.com - Investing.com South Africa
Spero Therapeutics stock soars on positive phase 3 trial results - Investing.com Australia
Spero Therapeutics’ Phase 3 Trial Meets Primary Endpoint - TipRanks
Spero Therapeutics and GSK Announce PIVOT-PO Phase 3 Study - GlobeNewswire
Spero Therapeutics and GSK Announce PIVOT-PO Phase 3 Study for Tebipenem HBr Stopped Early for Efficacy Following Review by Independent Data Monitoring Committee | SPRO Stock News - GuruFocus
Breakthrough UTI Treatment Success: First-Ever Oral Carbapenem Shows Early Phase 3 Win in $6B Market - Stock Titan
Analyzing Perrigo (NYSE:PRGO) & Spero Therapeutics (NASDAQ:SPRO) - Defense World
Spero Therapeutics, Inc. (SPRO) Reports Q1 Loss, Misses Revenue Estimates - MSN
Spero Therapeutics Announces First Quarter 2025 Operating Results and Provides a Business Update - The Manila Times
Spero Therapeutics (SPRO) to Release Earnings on Wednesday - Defense World
Spero Therapeutics Advances Phase 3 Trial With Strong Cash Position, Welcomes New CEO - Stock Titan
SPERO THERAPEUTICS Earnings Results: $SPRO Reports Quarterly Earnings - Nasdaq
Spero Therapeutics Inc (SPRO) Q1 2025: Everything You Need To Kn - GuruFocus
Spero Therapeutics, Inc. (NASDAQ:SPRO) Shares Bought by JPMorgan Chase & Co. - Defense World
Spero Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on Tuesday, May 13, 2025 - The Manila Times
Spero Therapeutics to Report First Quarter 2025 Financial - GlobeNewswire
Spero Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update ... - Eagle-Tribune
Renaissance Technologies LLC Increases Stake in Spero Therapeutics, Inc. (NASDAQ:SPRO) - Defense World
Spero Therapeutics Appoints Esther Rajavelu as CEO - citybiz
New Leadership Announcement for Spero Therapeutics (SPRO) | SPRO Stock News - GuruFocus
Spero Therapeutics appoints new CEO and board nominee - Investing.com
Spero Therapeutics Appoints Esther Rajavelu As President And Chief Executive Officer - marketscreener.com
Spero Therapeutics Appoints Esther Rajavelu as President and Chief Executive Officer - GlobeNewswire
Spero Therapeutics Promotes CFO to CEO Role as Critical Phase 3 Trial Results Approach - Stock Titan
Spero Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Prudential Financial Inc. Acquires Shares of 49,200 Spero Therapeutics, Inc. (NASDAQ:SPRO) - Defense World
Spero Therapeutics stock hits 52-week low at $0.51 amid challenges - Investing.com Canada
Spero Therapeutics stock hits 52-week low at $0.51 amid challenges By Investing.com - Investing.com South Africa
Bronstein, Gewirtz & Grossman, LLC Notifies Spero Therapeutics, Inc. (SPRO) Shareholders of Class Action and Encourages Investors to Contact the Firm - Business Wire
Spero Therapeutics, Inc. CLASS ACTION Alert: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the Eastern District of New York against Spero Therapeutics, Inc. - MarketScreener
Virtu Financial LLC Makes New $47,000 Investment in Spero Therapeutics, Inc. (NASDAQ:SPRO) - Defense World
Spero Therapeutics Inc (SPRO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.89%
3.74%
자본화:
|
볼륨(24시간):